Patents by Inventor Philip Marks
Philip Marks has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20100022751Abstract: A single polypeptide is provided which comprises first and second domains. The first domain enables the polypeptide to cleave one or more vesicle or plasma-membrane associated proteins essential to exocytosis, and the second domain enables the polypeptide to be translocated into a target cell or increases the solubility of the polypeptide, or both. The polypeptide thus combines useful properties of a clostridial toxin, such as a botulinum or tetanus toxin, without the toxicity associated with the natural molecule. The polypeptide can also contain a third domain that targets it to a specific cell, rendering the polypeptide useful in inhibition of exocytosis in target cells. Fusion proteins comprising the polypeptide, nucleic acids encoding the polypeptide and methods of making the polypeptide are also provided. Controlled activation of the polypeptide is possible and the polypeptide can be incorporated into vaccines and toxin assays.Type: ApplicationFiled: February 11, 2009Publication date: January 28, 2010Applicants: SYNTAXIN LIMITED, THE HEALTH PROTECTION AGENCYInventors: Clifford Charles Shone, Conrad Padraig Quinn, Keith Alan Foster, John Chaddock, Philip Marks, J. Mark Sutton, Patrick Stancombe, Jonathan Wayne
-
Patent number: 7640130Abstract: Systems and methods for effectuating verification and certification of verifiable devices. Preferably, but not necessarily, such certification occurs or is communicated remotely. A verifiable device may be directly or indirectly connected to an appropriate regulatory agency through a communication mechanism. One or more tests may be performed on the verifiable device to verify that the device is functioning properly. The test results are directly or indirectly transmitted to the regulatory agency. If the tests were passed then the verifiable device may be approved for use. When self-certification or remote certification is provided for, the need for in-person verification and certification procedures by agency personnel may be eliminated.Type: GrantFiled: October 24, 2007Date of Patent: December 29, 2009Assignee: Mettler-Toledo, Inc.Inventors: John Scott Churan, Philip Mark Metzler
-
Publication number: 20090274708Abstract: Antigenic compositions are provided comprising a single chain polypeptide comprising first and second domains, wherein said first domain is a clostridial neurotoxin light chain or a fragment or a variant thereof and is capable of cleaving one or more vesicle or plasma membrane associated proteins essential to exocytosis; and said second domain is a clostridial neurotoxin heavy chain HN portion or a fragment or a variant thereof, wherein said second domain is capable of (i) translocating the polypeptide into a cell or (ii) increasing the solubility of the polypeptide compared to the solubility of the first domain on its own or (iii) both translocating the polypeptide into a cell and increasing the solubility of the polypeptide compared to the solubility of the first domain on its own; and wherein the second domain lacks a functional C-terminal part of a clostridial neurotoxin heavy chain designated HC thereby rendering the polypeptide incapable of binding to cell surface receptors that are the natural cell surType: ApplicationFiled: March 6, 2009Publication date: November 5, 2009Applicants: Health Protection Agency, Syntaxin LimitedInventors: Charles Clifford SHONE, Conrad Padraig Quinn, Keith Alan Foster, John Chaddock, Philip Marks, J. Mark Sutton, Patrick Stancombe, Jonathan Wayne
-
Publication number: 20090246827Abstract: A single polypeptide is provided which comprises first and second domains. The first domain enables the polypeptide to cleave one or more vesicle or plasma-membrane associated proteins essential to exocytosis, and the second domain enables the polypeptide to be translocated into a target cell or increases the solubility of the polypeptide, or both. The polypeptide thus combines useful properties of a clostridial toxin, such as a botulinum or tetanus toxin, without the toxicity associated with the natural molecule. The polypeptide can also contain a third domain that targets it to a specific cell, rendering the polypeptide useful in inhibition of exocytosis in target cells. Fusion proteins comprising the polypeptide, nucleic acids encoding the polypeptide and methods of making the polypeptide are also provided. Controlled activation of the polypeptide is possible and the polypeptide can be incorporated into vaccines and toxin assays.Type: ApplicationFiled: July 17, 2008Publication date: October 1, 2009Applicants: SYNTAXIN LIMITED, THE HEALTH PROTECTION AGENCYInventors: Clifford Charles Shone, Conrad Padraig Quinn, Keith Alan Foster, John Chaddock, Philip Marks, J. Mark Sutton, Patrick Stancombe, Jonathan Wayne
-
Publication number: 20090148888Abstract: A single polypeptide is provided which comprises first and second domains. The first domain enables the polypeptide to cleave one or more vesicle or plasma-membrane associated proteins essential to exocytosis, and the second domain enables the polypeptide to be translocated into a target cell or increases the solubility of the polypeptide, or both. The polypeptide thus combines useful properties of a clostridial toxin, such as a botulinum or tetanus toxin, without the toxicity associated with the natural molecule. The polypeptide can also contain a third domain that targets it to a specific cell, rendering the polypeptide useful in inhibition of exocytosis in target cells. Fusion proteins comprising the polypeptide, nucleic acids encoding the polypeptide and methods of making the polypeptide are also provided. Controlled activation of the polypeptide is possible and the polypeptide can be incorporated into vaccines and toxin assays.Type: ApplicationFiled: January 27, 2009Publication date: June 11, 2009Applicants: SYNTAXIN LIMITED, THE HEALTH PROTECTION AGENCYInventors: Clifford Charles Shone, Conrad Padraig Quinn, Keith Alan Foster, John Chaddock, Philip Marks, J. Mark Sutton, Patrick Stancombe, Jonathan Wayne
-
Publication number: 20090035822Abstract: A single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a Targeting Moiety that is capable of binding to a Binding Site on the nociceptive sensory afferent, which Binding Site is capable of undergoing endocytosis to be incorporated into an endosome within the nociceptive sensory afferent; a protease cleavage site at which site the fusion protein is cleavable by a protease, wherein the protease cleavage site is located between the non-cytotoxic protease or fragment thereof and the Targeting Moiety; and a translocation domain that is capable of translocating the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent. Nucleic acid sequences encoding the polypeptide fusion proteins, methods of preparing same and uses thereof are also described.Type: ApplicationFiled: August 6, 2007Publication date: February 5, 2009Inventors: Keith Foster, John Chaddock, Philip Marks, Patrick Stancombe, Kei Roger Aoki, Joseph Francis, Lance Steward
-
Publication number: 20090004174Abstract: The invention provides a single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of a target cell; a Targeting Moiety that is capable of binding to a Binding Site on the target cell, which Binding Site is capable of undergoing endocytosis to be incorporated into an endocome within the target cell; a protease cleaving site at which site the fusion protein is cleavable by the protease, wherein the protease cleavage site is located between the non-cytotoxic protease or fragment thereof and the Targeting Moiety; and the translocation domain that is capable of translocating the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the target cell.Type: ApplicationFiled: December 1, 2005Publication date: January 1, 2009Applicant: SYNTAXIN LIMITEDInventors: Keith Alan Foster, John Chaddock, Philip Marks, Patrick Stancombe, Lyndsey Durose
-
Publication number: 20080287572Abstract: Curable wood particle composites curable by the Michael addition reaction in the presence of strong base catalyst are disclosed, along with a method for making those curable wood particle composites. Cured wood particle composites are also disclosed, along with a method of making those cured wood particle composites.Type: ApplicationFiled: May 1, 2008Publication date: November 20, 2008Inventors: Eric Gustave Lundquist, Allen Philip Marks
-
Publication number: 20080287571Abstract: Curable wood particle composites curable by the Michael addition reaction in the presence of weak base catalyst are disclosed, along with a method for making those curable wood particle composites. Cured wood particle composites are also disclosed, along with a method of making those cured wood particle composites.Type: ApplicationFiled: May 1, 2008Publication date: November 20, 2008Inventors: Eric Gustave Lundquist, Allen Philip Marks
-
Patent number: 7452543Abstract: A class of novel agents that are able to modify nociceptive afferent function is provided. The agents may inhibit the release of neurotransmitters from discrete populations of neurones and thereby reduce or preferably prevent the transmission of afferent pain signals from peripheral to central pain fibers. They comprise a galactose-binding lectin linked to a derivative of a clostridial neurotoxin. The derivative of the clostridial neurotoxin comprises the L-chain, or a fragment thereof, which includes the active proteolytic enzyme domain of the light (L) chain, linked to a molecule or domain with membrane translocating activity. The agents may be used in or as pharmaceuticals for the treatment of pain, particular chronic pain.Type: GrantFiled: October 25, 2005Date of Patent: November 18, 2008Assignee: Syntaxin Ltd.Inventors: John Andrew Chaddock, Philip Marks, Michael John Duggan
-
Publication number: 20080103716Abstract: Systems and methods for effectuating verification and certification of verifiable devices. Preferably, but not necessarily, such certification occurs or is communicated remotely. A verifiable device may be directly or indirectly connected to an appropriate regulatory agency through a communication mechanism. One or more tests may be performed on the verifiable device to verify that the device is functioning properly. The test results are directly or indirectly transmitted to the regulatory agency. If the tests were passed then the verifiable device may be approved for use. When self-certification or remote certification is provided for, the need for in-person verification and certification procedures by agency personnel may be eliminated.Type: ApplicationFiled: October 24, 2007Publication date: May 1, 2008Applicant: Mettler-Toledo, Inc.Inventors: John Scott Churan, Philip Mark Metzler
-
Publication number: 20080064092Abstract: The invention provides a single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of a target cell; a Targeting Moiety that is capable of binding to a Binding Site on the target cell, which Binding Site is capable of undergoing endocytosis to be incorporated into an endosome within the target cell; a protease cleavage site at which site the fusion protein is cleavable by a protease, wherein the protease cleavage site is located between the non-cytotoxic protease or fragment thereof and the Targeting Moiety; and a translocation domain that is capable of translocating the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the target cell.Type: ApplicationFiled: September 11, 2007Publication date: March 13, 2008Applicant: SYNTAXIN LTD.Inventors: Keith FOSTER, John CHADDOCK, Philip MARKS, Patrick STANCOMBE, Lyndsey DUROSE
-
Publication number: 20070248626Abstract: A single polypeptide is provided which comprises first and second domains. The first domain enables the polypeptide to cleave one or more vesicle or plasma-membrane associated proteins essential to exocytosis, and the second domain enables the polypeptide to be translocated into a target cell or increases the solubility of the polypeptide, or both. The polypeptide thus combines useful properties of a clostridial toxin, such as a botulinum or tetanus toxin, without the toxicity associated with the natural molecule. The polypeptide can also contain a third domain that targets it to a specific cell, rendering the polypeptide useful in inhibition of exocytosis in target cells. Fusion proteins comprising the polypeptide, nucleic acids encoding the polypeptide and methods of making the polypeptide are also provided. Controlled activation of the polypeptide is possible and the polypeptide can be incorporated into vaccines and toxin assays.Type: ApplicationFiled: December 22, 2006Publication date: October 25, 2007Applicants: The Health Protection Agency, Ipsen LimitedInventors: Clifford Shone, Conrad Quinn, Keith Foster, John Chaddock, Philip Marks, J. Sutton, Patrick Stancombe, Jonathan Wayne
-
Publication number: 20070184070Abstract: A single polypeptide is provided which comprises first and second domains. The first domain enables the polypeptide to cleave one or more vesicle or plasma-membrane associated proteins essential to exocytosis, and the second domain enables the polypeptide to be translocated into a target cell or increases the solubility of the polypeptide, or both. The polypeptide thus combines useful properties of a clostridial toxin, such as a botulinum or tetanus toxin, without the toxicity associated with the natural molecule. The polypeptide can also contain a third domain that targets it to a specific cell, rendering the polypeptide useful in inhibition of exocytosis in target cells. Fusion proteins comprising the polypeptide, nucleic acids encoding the polypeptide and methods of making the polypeptide are also provided. Controlled activation of the polypeptide is possible and the polypeptide can be incorporated into vaccines and toxin assays.Type: ApplicationFiled: March 14, 2007Publication date: August 9, 2007Inventors: Clifford Shone, Conrad Quinn, Keith Foster, John Chaddock, Philip Marks, J. Sutton, Patrick Stancombe, Jonathan Wayne
-
Patent number: 7224935Abstract: A method of showing approval or disapproval of an item overheard on an audio system. The method includes sending an item via radio waves to an audio system, listening to the item on the audio system and activating a button to indicate approval or disapproval of the item.Type: GrantFiled: November 29, 2000Date of Patent: May 29, 2007Assignee: Visteon Global Technologies, Inc.Inventors: Andrew Albert Messina, Jack Harold King, Michael Chrysochoos, Philip Mark Bator, Richard Zerod, Taras O. Fedak
-
Patent number: 7192596Abstract: A single polypeptide is provided which comprises first and second domains. The first domain enables the polypeptide to cleave one or more vesicle or plasma-membrane associated proteins essential to exocytosis, and the second domain enables the polypeptide to be translocated into a target cell or increases the solubility of the polypeptide, or both. The polypeptide thus combines useful properties of a clostridial toxin, such as a botulinum or tetanus toxin, without the toxicity associated with the natural molecule. The polypeptide can also contain a third domain that targets it to a specific cell, rendering the polypeptide useful in inhibition of exocytosis in target cells. Fusion proteins comprising the polypeptide, nucleic acids encoding the polypeptide and methods of making the polypeptide are also provided. Controlled activation of the polypeptide is possible and the polypeptide can be incorporated into vaccines and toxin assays.Type: GrantFiled: September 12, 2002Date of Patent: March 20, 2007Assignee: The Health Protection Agency Ipsen LimitedInventors: Clifford Charles Shone, Conrad Padraig Quinn, Keith Alan Foster, John Chaddock, Philip Marks, J. Mark Sutton, Patrick Stancombe, Jonathan Wayne
-
Patent number: D535389Type: GrantFiled: April 22, 2005Date of Patent: January 16, 2007Assignee: Wm. Wrigley Jr. CompanyInventors: Barbara Z. Stawski, Thomas M. Mindak, Ingo C. Theurer, Philip Mark Soukup, Stefan Johannes Brehm
-
Patent number: D535741Type: GrantFiled: April 22, 2005Date of Patent: January 23, 2007Assignee: Wm. Wrigley Jr. CompanyInventors: Barbara Z. Stawski, Thomas M. Mindak, Ingo C. Theurer, Philip Mark Soukup, Stefan Johannes Brehm
-
Patent number: D550833Type: GrantFiled: April 22, 2005Date of Patent: September 11, 2007Assignee: Wm. Wrigley Jr. CompanyInventors: Barbara Z. Stawski, Thomas M. Mindak, Ingo C. Theurer, Philip Mark Soukup, Stefan Johannes Brehm
-
Patent number: D557797Type: GrantFiled: April 22, 2005Date of Patent: December 18, 2007Assignee: Wm. Wrigley Jr. CompanyInventors: Barbara Z. Stawski, Thomas M. Mindak, Ingo C. Theurer, Philip Mark Soukup, Stefan Johannes Brehm